| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5826295 | Current Opinion in Pharmacology | 2013 | 9 Pages |
Abstract
⺠First oral kinase inhibitor drug approved by FDA for rheumatoid disease. ⺠Intense activity to expand the utility of JAK inhibitors in other auto-immune indications. ⺠Focus is on discovering inhibitors of the JAK family with different and more selective profiles. ⺠Progress is also being made with orally active Syk inhibitors. ⺠Last two to three years have been transformative for kinase inhibitors in auto-immune diseases.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
David L Simmons,